Healthcare analytics firm Airfinity cut its U.S. market forecast for respiratory syncytial virus (RSV) vaccines in older adults by as much as 64% this week after a panel of CDC experts narrowed their recommendations on RSV immunizations last month.

Airfinity revised its forecast…